Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
C4 Therapeutics, Inc.
C4 TherapeuticsAI Executive Summary
AI-powered analysis of 8-K filing content
C4 Therapeutics entered into a Research Collaboration and License Agreement with Roche on April 8, 2026, to discover, develop, and commercialize degrader-antibody conjugates for cancer therapy. This strategic partnership leverages their existing relationship and represents a significant validation of C4T's technology platform.
Key Takeaways
C4 Therapeutics partnered with Roche, a major pharmaceutical company, to develop degrader-antibody conjugates (DACs) targeting cancer
The collaboration builds on a pre-existing material relationship between the two companies, indicating strategic alignment
2 more takeaways